Repare Therapeutics Inc. (RPTX)
NASDAQ: RPTX · Real-Time Price · USD
1.290
-0.030 (-2.27%)
At close: Feb 21, 2025, 4:00 PM
1.260
-0.030 (-2.33%)
After-hours: Feb 21, 2025, 5:14 PM EST
Repare Therapeutics Stock Forecast
RPTX's stock price has decreased by -79.46% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Repare Therapeutics stock have an average target of 7.00, with a low estimate of 4.00 and a high estimate of 10. The average target predicts an increase of 442.64% from the current stock price of 1.29.
Analyst Consensus: Strong Buy
* Price targets were last updated on Dec 13, 2024.
Analyst Ratings
The average analyst rating for Repare Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 2 | 2 | 2 |
| Buy | 1 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 1 | 1 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 13, 2024 |
| Stifel | Stifel | Strong Buy Maintains $9 → $4 | Strong Buy | Maintains | $9 → $4 | +210.08% | Dec 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +675.19% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +675.19% | Oct 24, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | +675.19% | Sep 23, 2024 |
Financial Forecast
Revenue This Year
57.35M
from 51.13M
Increased by 12.15%
Revenue Next Year
7.99M
from 57.35M
Decreased by -86.07%
EPS This Year
-2.15
from -2.23
EPS Next Year
-2.74
from -2.15
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 65.7M | 21.0M | 21.0M | |||
| Avg | 57.3M | 8.0M | 8.6M | |||
| Low | 52.4M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 28.5% | -63.4% | 162.8% | |||
| Avg | 12.2% | -86.1% | 7.1% | |||
| Low | 2.5% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -2.14 | -1.86 | -1.24 |
| Avg | -2.15 | -2.74 | -2.35 |
| Low | -2.18 | -3.50 | -3.61 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.